Karuna Therapeutics (Nasdaq:KRTX) - Prezzo delle azioni, notizie e analisi

KRTX Panoramica delle azioni

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Maggiori dettagli

KRTX analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	5/6
Prestazioni passate	0/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Negoziato a 78% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 60.1% all'anno

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( $654K )

Gli azionisti sono stati diluiti nell'ultimo anno

Prezzo delle azioni volatile negli ultimi 3 mesi

Karuna Therapeutics, Inc. Concorrenti

Incyte

NasdaqGS:INCY

US$13.8b

BioMarin Pharmaceutical

NasdaqGS:BMRN

US$12.2b

Vaxcyte

NasdaqGS:PCVX

US$11.0b

Exelixis

NasdaqGS:EXEL

US$10.2b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Karuna Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$329.83
Massimo di 52 settimane	US$329.99
Minimo di 52 settimane	US$158.38
Beta	1.15
1Variazione di 1 mese	3.64%
Variazione a 3 mesi	50.58%
Variazione di 1 anno	80.73%
3Variazione a 3 anni	169.65%
Variazione a 5 anni	n/a
Variazione dall'IPO	1,547.50%

Notizie e aggiornamenti recenti

Recent updates

Here's Why We're Not At All Concerned With Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn Situation

Feb 20

Karuna Therapeutics, Inc. (NASDAQ:KRTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Nov 06

Best Performing Stocks

Sep 23

Karuna Therapeutics: This Ship Has Sailed

Sep 09

Karuna Therapeutics GAAP EPS of -$2.17 misses by $0.10, revenue of $5.28M

Aug 08

Karuna Therapeutics: Front-Running KarXT Phase 3

Jun 26

Karuna Therapeutics (NASDAQ:KRTX) Is In A Good Position To Deliver On Growth Plans

May 10

Rendimenti per gli azionisti

	KRTX	US Biotechs	US Mercato
7D	3.3%	2.5%	2.2%
1Y	80.7%	16.1%	31.6%

Ritorno vs Industria: KRTX ha superato il US Biotechs che ha restituito 16.1 % nell'ultimo anno.

Rendimento vs Mercato: KRTX ha superato il mercato US che ha restituito 31.6 % nell'ultimo anno.

Volatilità dei prezzi

Is KRTX's price volatile compared to industry and market?
KRTX volatility
KRTX Average Weekly Movement	13.9%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: Il prezzo delle azioni di KRTX è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di KRTX è aumentata da 8% a 14% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2009	339	Bill Meury	www.karunatx.com

Karuna Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Karuna Therapeutics con la sua capitalizzazione di mercato?
KRTX statistiche fondamentali
Capitalizzazione di mercato	US$12.58b
Guadagni(TTM)	-US$433.68m
Ricavi(TTM)	US$654.00k

Over9,999x

Rapporto P/S

-29.0x

Rapporto P/E

KRTX è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
KRTX Conto economico (TTM)
Ricavi	US$654.00k
Costo del fatturato	US$0
Profitto lordo	US$654.00k
Altre spese	US$434.33m
Guadagni	-US$433.68m

Ultimi guadagni dichiarati

Dec 31, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-11.37
Margine lordo	100.00%
Margine di profitto netto	-66,311.93%
Rapporto debito/patrimonio netto	0%

Come si è comportato KRTX nel lungo periodo?

Vedi performance storica e confronto

KRTX Panoramica delle azioni

Premi

Analisi del rischio

Karuna Therapeutics, Inc. Concorrenti

NasdaqGS:INCY

US$13.8b

NasdaqGS:BMRN

US$12.2b

NasdaqGS:PCVX

US$11.0b

NasdaqGS:EXEL

US$10.2b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Karuna Therapeutics, Inc. Files Form 15

Karuna Therapeutics, Inc.(NasdaqGM:KRTX) dropped from NASDAQ Composite Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others.

Chief Medical Officer notifies of intention to sell stock

Consensus revenue estimates increase by 11%, EPS downgraded

Board Member exercised options to buy US$9.9m worth of stock.

Recent updates

Karuna Therapeutics, Inc. Files Form 15

Karuna Therapeutics, Inc.(NasdaqGM:KRTX) dropped from NASDAQ Composite Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others.

Chief Medical Officer notifies of intention to sell stock

Consensus revenue estimates increase by 11%, EPS downgraded

Board Member exercised options to buy US$9.9m worth of stock.

Full year 2023 earnings: EPS and revenues miss analyst expectations

Karuna Therapeutics: Getting Sold Short

Chief Medical Officer notifies of intention to sell stock

Price target increased by 7.2% to US$327

Karuna Therapeutics, Inc. Announces Resignation of Steve Paul as Chief Scientific Officer and President of Research and Development

Chief Medical Officer notifies of intention to sell stock

Forecast to breakeven in 2026

Consensus revenue estimates decrease by 23%

Consensus revenue estimates decrease by 22%

Price target increased by 9.9% to US$291

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.6 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.5 billion.

Karuna Therapeutics, Inc. Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia

New minor risk - Profitability

Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for Karxt for the Treatment of Schizophrenia

Karuna Therapeutics, Inc. Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia

Chief Medical Officer notifies of intention to sell stock

Consensus revenue estimates decrease by 55%

New minor risk - Profitability

Third quarter 2023 earnings released: US$3.16 loss per share (vs US$2.38 loss in 3Q 2022)

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress

Karuna Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Chief Medical Officer notifies of intention to sell stock

Karuna Therapeutics, Inc. Submits New Drug Application to U.S. Food and Drug Administration for Karxt for the Treatment of Schizophrenia

We're Hopeful That Karuna Therapeutics (NASDAQ:KRTX) Will Use Its Cash Wisely

Director exercised options and sold US$2.5m worth of stock

New minor risk - Profitability

Karuna Therapeutics, Inc. Announces Chief Financial Officer Changes

Director exercised options and sold US$2.6m worth of stock

Karuna Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Director notifies of intention to sell stock

We're Not Very Worried About Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn Rate

CFO & Secretary notifies of intention to sell stock

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting

Consensus revenue estimates increase by 20%

Co-Founder & COO notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$838k worth of stock

Independent Director exercised options and sold US$96k worth of stock

Chief Medical Officer exercised options and sold US$920k worth of stock

Consensus revenue estimates fall by 85%

CFO & Secretary notifies of intention to sell stock

Here's Why We're Not At All Concerned With Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn Situation

Chief Medical Officer notifies of intention to sell stock

Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer

Independent Director exercised options and sold US$113k worth of stock

CFO & Secretary exercised options to buy US$2.3m worth of stock.

Chief Medical Officer exercised options and sold US$965k worth of stock

Karuna Therapeutics, Inc. Announces Executive Changes, Effective January 3, 2023

Co-Founder & COO exercised options and sold US$168k worth of stock

Chief Medical Officer notifies of intention to sell stock

Consensus revenue estimates fall by 25%

Karuna Therapeutics, Inc. (NASDAQ:KRTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Co-Founder & COO exercised options and sold US$444k worth of stock